Originator Company: VCANBIO Cell & Gene Engineering Corp Ltd Active Companies:
As no development has been reported for some time, this program is assumed to be discontinued. Zhongyuan Union Stem Cell Bio-Engineering , via its subsidiary Alliancells-PuRui Bioscience , was developing cord blood-derived cytokine-induced killer (CIK) cells for the potential treatment of solid tumors. In July 2013, a phase I trial was being planned. In April 2015, recruitment was started in China. At that time, trial completion was expected in June 2016 [ 1586517 ].
Cancer
No Development Reported
Anticancer; Natural killer cell stimulator